EW
SUPN icon

Evoke Wealth’s Supernus Pharmaceuticals SUPN Stock Holding History

Evoke Wealth’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-607
Closed -$16.7K – 1448
2019
Q3 		$16.7K Buy
+607
New +$18K ﹤0.01% 702

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Evoke Wealth's SUPN Position: Q4 2019 in Review

Evoke Wealth sold out of Supernus Pharmaceuticals (SUPN) in Q4 2019, closing a stake of 607 shares — an estimated $16.7K sold.

Evoke Wealth first reported a position in SUPN in Q3 2019 and held it in 1 quarter. The position peaked at $16.7K in Q3 2019. 235 funds tracked by Wall St. Rank hold SUPN as of Q4 2019.

  • Evoke Wealth reported no remaining Supernus Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Evoke Wealth sold 607 Supernus Pharmaceuticals shares in Q4 2019, an estimated $16.7K.
  • Evoke Wealth first reported a position in Supernus Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Evoke Wealth's Supernus Pharmaceuticals position peaked at $16.7K in Q3 2019.
  • 235 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2019.

Based on Evoke Wealth's 13F filing for Q4 2019, filed 7 Feb 2020.